Atara Biotherapeutics Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,800 Shares
Atara Biotherapeutics Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,800 shares of Atara Biotherapeutics stock in a transaction dated Friday, October 14th. The stock was sold at an average price of $15.96, for a total value of $76,608.00. Following the sale, the chief executive officer now directly owns 549,136 shares of the company’s stock, valued at $8,764,210.56. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Shares of Atara Biotherapeutics Inc. (NASDAQ:ATRA) traded up 0.62% during trading on Monday, reaching $16.15. The company had a trading volume of 183,418 shares. Atara Biotherapeutics Inc. has a 52-week low of $13.31 and a 52-week high of $40.80. The stock’s market capitalization is $465.30 million. The stock has a 50 day moving average of $19.63 and a 200 day moving average of $20.24.
Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Monday, August 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.05. Equities research analysts forecast that Atara Biotherapeutics Inc. will post ($2.85) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-4800-shares.html
A number of institutional investors have recently modified their holdings of ATRA. Eagle Asset Management Inc. boosted its position in shares of Atara Biotherapeutics by 0.8% in the third quarter. Eagle Asset Management Inc. now owns 980,673 shares of the company’s stock worth $20,976,000 after buying an additional 8,081 shares in the last quarter. Creative Planning acquired a new position in shares of Atara Biotherapeutics during the third quarter worth about $213,000. Capital Impact Advisors LLC acquired a new position in shares of Atara Biotherapeutics during the third quarter worth about $299,000. Franklin Street Advisors Inc. NC acquired a new position in shares of Atara Biotherapeutics during the third quarter worth about $214,000. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Atara Biotherapeutics by 24.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 66,295 shares of the company’s stock worth $1,493,000 after buying an additional 13,020 shares in the last quarter. 75.58% of the stock is currently owned by hedge funds and other institutional investors.
ATRA has been the subject of a number of recent analyst reports. Jefferies Group reaffirmed a “buy” rating and set a $25.00 price target on shares of Atara Biotherapeutics in a report on Tuesday, August 9th. JMP Securities reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Saturday, July 9th. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 2nd. Goldman Sachs Group Inc. downgraded Atara Biotherapeutics from a “neutral” rating to a “sell” rating and reduced their target price for the company from $23.00 to $16.00 in a report on Thursday, September 15th. Finally, Citigroup Inc. boosted their target price on Atara Biotherapeutics from $8.00 to $10.00 and gave the company a “sell” rating in a report on Friday, August 19th. Two analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $26.14.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.